Placebo Saline Infusion

DRUG4 trials

Sponsors

NuvOx LLC, CatalYm GmbH, Mansoura University

Conditions

Adult Solid TumorBlood Loss, SurgicalCesarean SectionChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 CompoundGlioblastoma MultiformeMetastatic Non-Squamous Non-Small Cell Lung CancerPostpartum Hemorrhage

Phase 2

A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

Active, not recruitingNCT03862430

NuvOx LLCGlioblastoma Multiforme

Start: 2023-03-31End: 2027-09-30Target: 87Updated: 2026-08-06

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

RecruitingNCT07219459

CatalYm GmbHChild-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound, Unresectable or Metastatic Hepatocellular Carcinoma

Start: 2026-03-19End: 2031-09-01Target: 104Updated: 2026-07-21

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

RecruitingNCT07246863

CatalYm GmbHAdult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer

Start: 2025-10-07End: 2031-10-01Target: 131Updated: 2026-08-19

Phase 4

Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial

Not yet recruitingNCT07636421

Mansoura UniversityBlood Loss, Surgical, Cesarean Section, Postpartum Hemorrhage +1

Start: 2026-08-01End: 2028-08-01Target: 332Updated: 2026-06-09

Related Papers

A phase 2 double-blind, randomized, prospective, placebo-controlled study of NanO₂ combined with radiation and temozolomide in patients with newly diagnosed glioblastoma: RESTORE.

Journal of Clinical Oncology2026-05-27